How to use ibrutinib
The emergence of new targeted drugs, affecting B-cell receptor signaling pathway opens a new page in the treatment of chronic lymphocytic leukemia (CLL). It is not simply expanding choice, it will likely to change total strategy of CLL management. Clinical trials have shown improvement of overall su...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
ABV-press
2017-04-01
|
| Series: | Onkogematologiâ |
| Subjects: | |
| Online Access: | https://oncohematology.abvpress.ru/ongm/article/view/229 |
| id |
doaj-c228c7bf7fb54c1484aaf0ab3c5c1bfe |
|---|---|
| record_format |
Article |
| spelling |
doaj-c228c7bf7fb54c1484aaf0ab3c5c1bfe2021-07-29T09:03:05ZrusABV-pressOnkogematologiâ1818-83462017-04-01121334310.17650/1818-8346-2017-12-1-33-43227How to use ibrutinibЕ. А. Nikitin0V. I. Vorobiev1М. А. Panteleev2G. E. Gendlin3V. V. Ptushkin4S.P. Botkin City Clinical Hospital, Moscow Heаlthcare Department;S.P. Botkin City Clinical Hospital, Moscow Heаlthcare Department;National Scientific and Practical Center of Pediatric Hematology, Oncology and Immunnology named after Dmitry Rogachev, Ministry of Health of Russia;N.I. Pirogov Russian National Research Medical University, Ministry of Health of Russia;S.P. Botkin City Clinical Hospital, Moscow Heаlthcare Department;The emergence of new targeted drugs, affecting B-cell receptor signaling pathway opens a new page in the treatment of chronic lymphocytic leukemia (CLL). It is not simply expanding choice, it will likely to change total strategy of CLL management. Clinical trials have shown improvement of overall survival in CLL patients in both first line and relapsed disease settings. Targeted drugs lack typical complications of chemotherapy, such as myelosupression. However, they have their specific side effects that require particular attention to avoid unjustified dose reduction and treatment cessation. The present review focuses on practical use of ibrutinib, the first inhibitor of Bruton’s tyrosinkinase.https://oncohematology.abvpress.ru/ongm/article/view/229chronic lymphocytic leukemiatargeted drugsibrutini |
| collection |
DOAJ |
| language |
Russian |
| format |
Article |
| sources |
DOAJ |
| author |
Е. А. Nikitin V. I. Vorobiev М. А. Panteleev G. E. Gendlin V. V. Ptushkin |
| spellingShingle |
Е. А. Nikitin V. I. Vorobiev М. А. Panteleev G. E. Gendlin V. V. Ptushkin How to use ibrutinib Onkogematologiâ chronic lymphocytic leukemia targeted drugs ibrutini |
| author_facet |
Е. А. Nikitin V. I. Vorobiev М. А. Panteleev G. E. Gendlin V. V. Ptushkin |
| author_sort |
Е. А. Nikitin |
| title |
How to use ibrutinib |
| title_short |
How to use ibrutinib |
| title_full |
How to use ibrutinib |
| title_fullStr |
How to use ibrutinib |
| title_full_unstemmed |
How to use ibrutinib |
| title_sort |
how to use ibrutinib |
| publisher |
ABV-press |
| series |
Onkogematologiâ |
| issn |
1818-8346 |
| publishDate |
2017-04-01 |
| description |
The emergence of new targeted drugs, affecting B-cell receptor signaling pathway opens a new page in the treatment of chronic lymphocytic leukemia (CLL). It is not simply expanding choice, it will likely to change total strategy of CLL management. Clinical trials have shown improvement of overall survival in CLL patients in both first line and relapsed disease settings. Targeted drugs lack typical complications of chemotherapy, such as myelosupression. However, they have their specific side effects that require particular attention to avoid unjustified dose reduction and treatment cessation. The present review focuses on practical use of ibrutinib, the first inhibitor of Bruton’s tyrosinkinase. |
| topic |
chronic lymphocytic leukemia targeted drugs ibrutini |
| url |
https://oncohematology.abvpress.ru/ongm/article/view/229 |
| work_keys_str_mv |
AT eanikitin howtouseibrutinib AT vivorobiev howtouseibrutinib AT mapanteleev howtouseibrutinib AT gegendlin howtouseibrutinib AT vvptushkin howtouseibrutinib |
| _version_ |
1721249667734306816 |